2 options
Food and Drug Administration's Critical Path Initiative : hearing before a subcommittee of the Committee on Appropriations, United States Senate; One Hundred Tenth Congress, first session; special hearing: June 1, 2007; Salt Lake City, Utah.
Connect to full text Available online
View online- Format:
- Book
- Government document
- Author/Creator:
- United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, author.
- Series:
- United States. Congress. Senate. S. hrg. ; 110-293.
- S. hrg. ; 110-293
- Language:
- English
- Subjects (All):
- United States. Food and Drug Administration--Rules and practice.
- United States.
- United States. Food and Drug Administration.
- Biological products--United States.
- Biological products.
- Pharmaceutical industry--United States.
- Pharmaceutical industry.
- Drug development--United States.
- Drug development.
- Drugs--Research--United States.
- Drugs.
- Public-private sector cooperation--United States.
- Public-private sector cooperation.
- Drugs--Research.
- Genre:
- Online resources.
- Legislative hearings
- Rules
- Legislative hearings.
- Physical Description:
- 1 online resource (iii, 42 pages)
- Other Title:
- Critical Path Initiative
- Place of Publication:
- Washington : U.S. Government Printing Office, 2008.
- Summary:
- "In 2004 FDA called for a national effort to identify specific activities aimed at modernizing the delivery of health care, and they formally launched the agency's Critical Path Initiative. The term 'Critical Path' is used to describe the way that a potential drug or biological product or device can find its way from prototype or an idea to a viable medical product for use in patients. The initiative was born out of the agency's concern for the declining number of new medical products coming to the market. One of the strengths of the American economy has been the constant flow of new products in this area. And when the number starts to drop off, that is a legitimate reason for concern"--Page 1/2.
- Notes:
- Description based on online resource; title from PDF title screen (FDsys, viewed on Oct. 11, 2017).
- Distributed to some depository libraries in microfiche.
- Shipping list no.: 2008-0279-P.
- Includes bibliographical references.
- Electronic reproduction. [S.l.] : HathiTrust Digital Library, 2010.
- Other Format:
- Print version: United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies. Food and Drug Administration's Critical Path Initiative
- Microfiche version: United States. Congress. Senate. Committee on Appropriations. Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies. Food and Drug Administration's Critical Path Initiative
- OCLC:
- 680982200
- Access Restriction:
- Use copy Restrictions unspecified
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.